Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of D-0502 versus fulvestrant in previously treated ER-positive, HER2-negative advanced or metastatic breast cancer
CTR20220511Phase 3Active
- Sponsor
- InventisBio
- Start
- Sep 2022
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of taragarestrant in breast cancer, sponsored by InventisBio. Started Sep 2022; status: active.
02
Drugs
taragarestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20220511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220511.